<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(52)</volume><submitter>Ai S</submitter><pubmed_abstract>The &lt;i>cis&lt;/i>-diamminedichloroplatinum(ii) (DDP, cisplatin) is an important antitumor drug for the therapy of gastric cancer in clinics, but it is limited by its nonspecific tissue distribution and severe side effects. Here, an integrin targeted drug delivery system iRGD-heparin nanocarrier (iHP) was successfully synthesized. The iHP has several unique properties. First, this nanocarrier has excellent biodegradation due to its heparin biopolymer frame. Second, it is biocompatible because succinic anhydride-modified heparin has no anticoagulant activity and cell toxicity. We proved that from anticoagulant function evaluation and a cytotoxicity test. Third, iRGD was conjugated to the nanoparticles as an integrin-targeting ligand. Our results showed that iHP has precise targeting to integrin</pubmed_abstract><journal>RSC advances</journal><pagination>30012-30020</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9085286</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>An iRGD peptide conjugated heparin nanocarrier for gastric cancer therapy.</pubmed_title><pmcid>PMC9085286</pmcid><pubmed_authors>Liu Z</pubmed_authors><pubmed_authors>Ai S</pubmed_authors><pubmed_authors>Guan W</pubmed_authors><pubmed_authors>Zhen S</pubmed_authors><pubmed_authors>He X</pubmed_authors><pubmed_authors>Chu F</pubmed_authors><pubmed_authors>Sun F</pubmed_authors><pubmed_authors>Wang J</pubmed_authors></additional><is_claimable>false</is_claimable><name>An iRGD peptide conjugated heparin nanocarrier for gastric cancer therapy.</name><description>The &lt;i>cis&lt;/i>-diamminedichloroplatinum(ii) (DDP, cisplatin) is an important antitumor drug for the therapy of gastric cancer in clinics, but it is limited by its nonspecific tissue distribution and severe side effects. Here, an integrin targeted drug delivery system iRGD-heparin nanocarrier (iHP) was successfully synthesized. The iHP has several unique properties. First, this nanocarrier has excellent biodegradation due to its heparin biopolymer frame. Second, it is biocompatible because succinic anhydride-modified heparin has no anticoagulant activity and cell toxicity. We proved that from anticoagulant function evaluation and a cytotoxicity test. Third, iRGD was conjugated to the nanoparticles as an integrin-targeting ligand. Our results showed that iHP has precise targeting to integrin</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Aug</publication><modification>2025-04-19T21:43:38.581Z</modification><creation>2025-04-19T21:43:38.581Z</creation></dates><accession>S-EPMC9085286</accession><cross_references><pubmed>35547284</pubmed><doi>10.1039/c8ra05071f</doi></cross_references></HashMap>